Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 06 - 13 tags : Fda save search
Outset Medical Announces Shipment Hold on New Tablo Systems for Home Use Pending FDA Review and Clearance of Recent 510(K) Submission
Published: 2022-06-13 (Crawled : 23:00) - biospace.com/
OM | $2.46 5.13% 4.88% 640K
|
Health Technology
|
| O: -4.67%
H: 4.7%
C: 1.95%
fda clearance review home submission
SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System
Published: 2022-06-13 (Crawled : 21:00) - biospace.com/
SIBN | $15.265 -1.9% -1.93% 310K
|
Health Technology
|
| O: -3.68%
H: 0.58%
C: -1.08%
torq fda clearance system implant
FDA Approves First Systemic Treatment for Alopecia Areata
Published: 2022-06-13 (Crawled : 20:00) - fda.gov
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
treatment fda
Following bluebird's FDA Win, 4 Companies Aim High with New Gene Therapies
Published: 2022-06-13 (Crawled : 17:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda companies therapy
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -1.53%
H: 0.93%
C: -0.83%
keytruda fda application therapy cancer
LENSAR® Receives U.S. FDA Clearance of ALLY™ Adaptive Cataract Treatment System
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
LNSR | $3.26 0.31% 0.31% 14K
|
Health Technology
|
| O: -0.46%
H: 7.31%
C: 1.24%
lensar treatment fda clearance system
Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: -0.29%
H: 0.13%
C: -1.7%
treatment fda rare drug disease designation
Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome
Published: 2022-06-13 (Crawled : 12:00) - prnewswire.com
MNKKQ | $0.02
|
Manufacturing
|
| O: 0.33%
H: 9.48%
C: -75.33%
treatment fda resubmission
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.